Sun Pharmaceutical launched a binding bid to acquire Organon, while S&P Global Ratings assigned a BBB+ credit rating.
5 reports, 2 independent
Updated Sep 21
Gone quiet
Reached 4 outlets in its first 24 hours
- Reports
- 5
- Developments
- 2
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Sun Pharmaceutical launched a binding bid to acquire Organon, while S&P Global Ratings assigned a BBB+ credit rating.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Acquisition of Organon strengthens Sun Pharma's leadership in the Indian market and broadens its therapeutic presence.1 source
Sun Pharma bids $11.75B for Organon; S&P assigns BBB+ rating.1 source
Keep exploring
The entities involved
-
Sun Pharmaceutical
Indian multinational pharmaceutical company
Nothing else this week.
-
S&P Global Ratings
credit rating agency, subsidiary of S&P Global